Trial · NCT02621060

Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance

NCT02621060, Phase 2, Completed, University of Guadalajara; results first posted 2019-08-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance. Trials, record NCT02621060. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02621060

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance
NCT number: NCT02621060
Status: Completed
Phases: Phase 2
Enrollment: 30 participants, actual
Lead sponsor: University of Guadalajara
Conditions: Impaired Glucose Tolerance
Interventions: Placebo, Chlorogenic acid
First posted: 2015-12-03
Last updated: 2019-08-02
Results first posted: 2019-08-02

Source ClinicalTrials.gov

Registered outcomes22

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Fasting Plasma Glucose (FPG)	Week 12.	Reflect the fasting glucose level after a 10- to 12-h overnight fast.
Primary	2 Hours Plasma Glucose (2-h PG)	Week 12.	Subjects underwent a 2-h oral glucose tolerance test (2-h OGTT) by consuming 75-g of a dextrose load, and one sample was obtained 120 min after glucose administration.
Primary	Glycated Hemoglobin A1c (A1C)	Week 12.	Shows what a person's average blood glucose level was for the 2 to 3 months before the test high-performance.
Primary	Total Insulin Secretion	Week 12.	After intervention. Total insulin secretion was calculated with the Insulinogenic index (Δ ABC insulin / Δ ABC glucose).
Primary	First Phase of Insulin Secretion	Week 12.	After intervention with Stumvoll index
Primary	Insulin Sensitivity	Week 12.	After intervention Matsuda Index
Secondary	Area Under the Curve of Glucose	Week 12.	Area under the curve of glucose was obtained using the trapezoidal integration.
Secondary	Area Under the Curve of Insulin	Week 12.	Before and after intervention area under the curve of insulin
Secondary	Body Weight	Week 12.	The weight was measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12
Secondary	Body Mass Index	Week 12.	The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12

1 to 10 of 22Source ClinicalTrials.gov

See all 22 registered outcomes

Outcomes22

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Fasting Plasma Glucose (FPG)	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	mmol/L	MEDIAN
PRIMARY	2 Hours Plasma Glucose (2-h PG)	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	mmol/L	MEAN
PRIMARY	Glycated Hemoglobin A1c (A1C)	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	Percentage of A1C	MEAN
PRIMARY	Total Insulin Secretion	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	Unitless	MEAN
PRIMARY	First Phase of Insulin Secretion	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	Unitless	MEAN
PRIMARY	Insulin Sensitivity	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	Unitless	MEAN
SECONDARY	Area Under the Curve of Glucose	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	mmol/l/min	MEAN
SECONDARY	Area Under the Curve of Insulin	Week 12.		pmol/L/min	MEAN
SECONDARY	Body Weight	Week 12.	3 and 1 subjects dropout in the placebo and chlorogenic acid group respectively.	kg	MEAN
SECONDARY	Body Mass Index	Week 12.		kg/m^2	MEAN

1 to 10 of 22Source ClinicalTrials.gov

See all 22 outcomes

Results by group44

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Fasting Plasma Glucose (FPG)	Placebo	5.8	Standard Deviation 0.3	mmol/L
Fasting Plasma Glucose (FPG)	Chlorogenic Acid	5.5	Standard Deviation 0.4	mmol/L
2 Hours Plasma Glucose (2-h PG)	Placebo	9.0	Standard Deviation 0.8	mmol/L
2 Hours Plasma Glucose (2-h PG)	Chlorogenic Acid	8.5	Standard Deviation 0.4	mmol/L
Glycated Hemoglobin A1c (A1C)	Placebo	5.8	Standard Deviation 0.3	Percentage of A1C
Glycated Hemoglobin A1c (A1C)	Chlorogenic Acid	5.5	Standard Deviation 0.4	Percentage of A1C
Total Insulin Secretion	Placebo	0.55	Standard Deviation 0.26	Unitless
Total Insulin Secretion	Chlorogenic Acid	0.63	Standard Deviation 0.25	Unitless
First Phase of Insulin Secretion	Placebo	1281	Standard Deviation 818	Unitless
First Phase of Insulin Secretion	Chlorogenic Acid	1133	Standard Deviation 601	Unitless

1 to 10 of 44Source ClinicalTrials.gov

See all 44 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	15
Overall Study	STARTED	Chlorogenic Acid	15
Overall Study	COMPLETED	Placebo	12
Overall Study	COMPLETED	Chlorogenic Acid	14
Overall Study	NOT COMPLETED	Placebo	3
Overall Study	NOT COMPLETED	Chlorogenic Acid	1

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Diarrea	Gastrointestinal disorders	Placebo	3	15
other	Diarrea	Gastrointestinal disorders	Chlorogenic Acid	1	15
other	Headacha	Nervous system disorders	Placebo	0	15
other	Headacha	Nervous system disorders	Chlorogenic Acid	2	15
other	polyuria	Renal and urinary disorders	Placebo	2	15
other	polyuria	Renal and urinary disorders	Chlorogenic Acid	1	15
other	abdominal pain	Gastrointestinal disorders	Placebo	1	15
other	abdominal pain	Gastrointestinal disorders	Chlorogenic Acid	1	15
other	abdominal distention	Gastrointestinal disorders	Placebo	1	15
other	abdominal distention	Gastrointestinal disorders	Chlorogenic Acid	0	15

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Chlorogenic Acid
Total, other adverse events	Placebo	3	15
Total, other adverse events	Chlorogenic Acid	2	15
Total, serious adverse events	Placebo	0	15
Total, serious adverse events	Chlorogenic Acid	0	15

Source ClinicalTrials.gov

Papers12

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
10097917	BACKGROUND	PubMed
11208940	BACKGROUND	PubMed
15694706	BACKGROUND	PubMed
16551305	BACKGROUND	PubMed
17364278	BACKGROUND	PubMed
18370832	BACKGROUND	PubMed
18996826	BACKGROUND	PubMed
22079683	BACKGROUND	PubMed
23598536	BACKGROUND	PubMed
24039147	BACKGROUND	PubMed

1 to 10 of 12

See all 12 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Chlorogenic Acid vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02621060

GET https://conductscience.org/api/trials/v1/NCT02621060/registered?page=2

API reference For AI assistants